The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to
the Securities and Exchange Commission (SEC)
by insider Bigham Michael since year 2005.
The trader's CIK number is 1216917.
At the time of the last reporting, Bigham Michael was the Director of Paratek Pharmaceuticals, Inc. .
(stock ticker symbol PRTK).
See this page for all insider trading activities at Paratek Pharmaceuticals, Inc. .
| Trade Date | Symbol | Company Name (Issuer) | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|---|
| 2018-12-12 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 8,400 | 6.76 | 56,784 |
| 2018-10-15 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 6,300 | 8.96 | 56,448 |
| 2018-10-03 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 16,313 | 9.82 | 160,193 |
| 2018-07-02 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 22,500 | 9.97 | 224,325 |
| 2018-04-09 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 8,700 | 12.70 | 110,490 |
| 2018-02-05 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 4,000 | 14.22 | 56,880 |
| 2017-07-19 | PRTK | Paratek Pharmaceuticals, Inc. | Option Ex | 23,255 | 4.30 | 99,996 |
| 2017-07-05 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 5,075 | 23.58 | 119,663 |
| 2017-02-06 | PRTK | Paratek Pharmaceuticals, Inc. | Sale | 5,000 | 15.12 | 75,575 |
| 2016-06-23 | PRTK | Paratek Pharmaceuticals, Inc. | Buy | 20,000 | 13.45 | 269,020 |
| 2013-03-20 | SUPN | Supernus Pharmaceuticals Inc | Buy | 20,000 | 5.21 | 104,200 |
| 2013-03-22 | SUPN | Supernus Pharmaceuticals Inc | Buy | 15,000 | 5.65 | 84,795 |
| 2005-08-11 | XGEN | Xenogen Corp | Buy | 1,374,571 | 2.91 | 4,000,001 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Bigham Michael (Director of Paratek Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.